| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM197205182862009 |
| P698 | PubMed publication ID | 4553202 |
| P2093 | author name string | Bricker NS | |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 1093-1099 | |
| P577 | publication date | 1972-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". | |
| P478 | volume | 286 |
| Q36308619 | "Phosphatonins" and the regulation of phosphorus homeostasis |
| Q45043261 | 1 Endocrine manifestations of systemic disease |
| Q41134204 | Abnormal Gonadothrophin Secretion in Children with Chronic Renal Failure |
| Q41204671 | Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism |
| Q67065491 | Bicarbonate reabsorption in experimental renal disease: Effects of proportional reduction of sodium or phosphate intake |
| Q67867840 | Bicarbonate reabsorption in the dog with experimental renal disease |
| Q37119865 | Bone and mineral disorders in pre-dialysis CKD. |
| Q69826347 | Calcitriol deficiency with retained synthetic reserve in chronic renal failure |
| Q38097111 | Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. |
| Q57224881 | Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients |
| Q55509854 | Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. |
| Q92533944 | Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives |
| Q39940967 | Collagen metabolism, uremia and bone |
| Q90450534 | Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management |
| Q37939591 | Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients |
| Q40273181 | Dissociation of renal cyclic AMP and phosphate responses to parathyroid hormone in uremia |
| Q71079950 | Do Middle Molecules Cause Uremic Intoxication? (Con) |
| Q39900110 | Editorial: The kidney and uric acid excretion in man. |
| Q36902283 | Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure |
| Q41508632 | Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the "trade-off hypothesis". |
| Q34677226 | Endocrine abnormalities in chronic renal failure |
| Q41066745 | Endocrine disturbances of calcium metabolism in uremia: renal causes and systemic consequences |
| Q35541172 | Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis |
| Q50986471 | Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. |
| Q33929831 | Evidence that parathyroid hormone is not required for phosphate homeostasis in renal failure |
| Q41883512 | Factor VIII complex in uraemia and effects of haemodialysis |
| Q46275736 | Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. |
| Q44678823 | Fibroblast growth factor 23 in feline chronic kidney disease. |
| Q37162723 | Fibroblast growth factor-23: what we know, what we don't know, and what we need to know |
| Q34052255 | Food intolerance in humans |
| Q50638304 | Hearing Loss in Renal Disease: Clinical and Pathological Studies |
| Q39940973 | Hyperparathyroidism and renal failure |
| Q68013716 | Impaired metabolism of high density lipoprotein in uremic patients |
| Q40119457 | Increased Growth after Long-Term Oral 1α,25-Vitamin D3in Childhood Renal Osteodystrophy |
| Q40815750 | Increased nephron oxygen consumption: potential role in progression of chronic renal disease |
| Q46188041 | Is parathormone a cardiac toxin in uremia? |
| Q36561062 | Minimizing bone abnormalities in children with renal failure |
| Q48598808 | Nephrology at Washington University School of Medicine: my early days |
| Q38274050 | New methods and technologies for measuring uremic toxins and quantifying dialysis adequacy |
| Q52301663 | Nutritional Management of Chronic Renal Disease |
| Q53861205 | On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake |
| Q38594647 | Oral Manifestations of Chronic Kidney Disease and Renal Secondary Hyperparathyroidism: A Comparative Review |
| Q38319620 | Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats |
| Q39246280 | Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure |
| Q70377503 | Parathyroid hormone-independent adaptation of the renal handling of phosphate in response to renal mass reduction |
| Q71979486 | Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats |
| Q38572880 | Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. |
| Q40318301 | Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. |
| Q39800403 | Pediatric Parathyroid Disorders |
| Q36965142 | Phosphate Toxicity in CKD: The Killer among Us |
| Q24610674 | Phosphate and FGF-23 |
| Q44924140 | Phosphorus Restriction and Vitamin D Metabolism |
| Q38690013 | Physicochemical properties of radiographic contrast media, potential nephrotoxicity and prophylaxis |
| Q44600577 | Plasma calcium and magnesium fractions in chronic-renal-failure patients on maintenance haemodialysis |
| Q36667209 | Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD |
| Q52388436 | Proceedings from the symposium in honor of Neal S. Bricker. Denver, CO, May 7 and 8, 1993. Introduction. |
| Q58715560 | Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care |
| Q40470649 | Recent advances in calcium metabolism. II. Disorders of calcium homeostasis |
| Q34563650 | Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study |
| Q26852177 | Regulation of serum phosphate |
| Q37228467 | Remnant nephron physiology and the progression of chronic kidney disease |
| Q37953234 | Renal bone disease 1990: an unmet challenge for the nephrologist |
| Q40616661 | Renal bone disease. |
| Q40326767 | Renal insufficiency in geriatric dogs |
| Q68138560 | Repeat parathyroid operation associated with renal disease |
| Q66945765 | Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog |
| Q49074038 | Role of dialysable solutes in the mediation of uremic encephalopathy in the rat. |
| Q44071622 | Role of dietary phosphorus in the progression of renal failure |
| Q45991178 | Six-year dialysis freedom in end-stage renal disease. |
| Q44566979 | Some Aspects of Chronic Renal Failure |
| Q34488869 | Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. |
| Q92431473 | THE PREVALENCE OF BIOCHEMICAL ABNORMALITIES OF CHRONIC KIDNEY DISEASE. MINERAL AND BONE DISORDERS IN UNTREATED NON-DIALYSIS PATIENTS - A MULTICENTER STUDY |
| Q35914820 | The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease |
| Q35573642 | The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. |
| Q26865026 | The Trade-Off between Dietary Salt and Cardiovascular Disease; A Role for Na/K-ATPase Signaling? |
| Q39173994 | The Tubulointerstitial Pathophysiology of Progressive Kidney Disease |
| Q57227505 | The absorption of dietary phosphorus and calcium in hemodialysis patients |
| Q34326197 | The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia |
| Q36583342 | The case for routine parathyroid hormone monitoring |
| Q68602462 | The evolution of the science of pathologic physiology |
| Q33873107 | The importance of total kidney volume in evaluating progression of polycystic kidney disease |
| Q37846524 | The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder |
| Q40415829 | The pathogenesis of parathyroid gland hyperplasia in chronic renal failure |
| Q70435900 | The role of nutrition in the care of children with renal insufficiency |
| Q38086910 | The role of phosphorus in the pathophysiology of chronic kidney disease. |
| Q45051065 | The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease |
| Q42233431 | Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism |
| Q34328318 | Uremic toxicity: urea and beyond |
| Q34025119 | Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease |
| Q45028791 | Veterinary nephrology - yesterday and today |
| Q73067482 | Vitamin D analogs: from renal bone disease to osteoporosis |
| Q41736064 | Vitamin D and analogues in renal bone disease and implications for osteoporosis. |
| Q67584802 | What causes toxicity in uraemia? |
| Q67759000 | [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)] |
Search more.